相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
Odd Erik Johansen et al.
CARDIOVASCULAR DIABETOLOGY (2012)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
Cardiovascular Biology of the Incretin System
John R. Ussher et al.
ENDOCRINE REVIEWS (2012)
The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study
Benjamin M. Scirica et al.
AMERICAN HEART JOURNAL (2011)
EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE): A cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome
William B. White et al.
AMERICAN HEART JOURNAL (2011)
Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations
Wendy L. Bennett et al.
ANNALS OF INTERNAL MEDICINE (2011)
The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury
Yumei Ye et al.
BASIC RESEARCH IN CARDIOLOGY (2011)
Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks
Antonio R. Chacra et al.
DIABETES & VASCULAR DISEASE RESEARCH (2011)
Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
A. Garber et al.
DIABETES OBESITY & METABOLISM (2011)
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study
Tina Ken Schramm et al.
EUROPEAN HEART JOURNAL (2011)
Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
Hertzel C. Gerstein et al.
CIRCULATION (2010)
Effect of Intensive Compared With Standard Glycemia Treatment Strategies on Mortality by Baseline Subgroup Characteristics The Action to Control The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial
Jorge Calles-Escandon et al.
DIABETES CARE (2010)
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
D. R. Matthews et al.
DIABETES OBESITY & METABOLISM (2010)
Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
A. Schweizer et al.
DIABETES OBESITY & METABOLISM (2010)
The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans
Stefan Blech et al.
DRUG METABOLISM AND DISPOSITION (2010)
Vildagliptin A Review of its Use in Type 2 Diabetes Mellitus
Gillian M. Keating
DRUGS (2010)
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
T. Seck et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Impact of Type of Preadmission Sulfonylureas on Mortality and Cardiovascular Outcomes in Diabetic Patients with Acute Myocardial Infarction
Marianne Zeller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
The evolving place of incretin-based therapies in type 2 diabetes
Baptist Gallwitz
PEDIATRIC NEPHROLOGY (2010)
A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
Robert Frederich et al.
POSTGRADUATE MEDICINE (2010)
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
Debora Williams-Herman et al.
BMC ENDOCRINE DISORDERS (2010)
The role for saxagliptin within the management of type 2 diabetes mellitus: an update from the 2010 European Association for the Study of Diabetes (EASD) 46th annual meeting and the American Diabetes Association (ADA) 70th scientific session
Pablo J. Aschner
DIABETOLOGY & METABOLIC SYNDROME (2010)
Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?
Dario Giugliano et al.
ACTA DIABETOLOGICA (2009)
Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association
Jay S. Skyler et al.
DIABETES CARE (2009)
Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report
C. Abraira et al.
DIABETES OBESITY & METABOLISM (2009)
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
D. M. Nathan et al.
DIABETOLOGIA (2009)
Efficacy and Safety Comparison Between the DPP-4 Inhibitor Vildagliptin and the Sulfonylurea Gliclazide After Two Years of Monotherapy in Drug-naive Patients with Type 2 Diabetes
J. E. Foley et al.
HORMONE AND METABOLIC RESEARCH (2009)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Philip D. Home et al.
LANCET (2009)
Glucose control and vascular complications in veterans with type 2 diabetes (vol 360, pg 129, 2009)
Thomas Moritz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
William Duckworth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
Ioanna Tzoulaki et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10)
Robert Wilcox et al.
AMERICAN HEART JOURNAL (2008)
The growing burden of diabetes mellitus in the US elderly population
Frank A. Sloan et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Cardiovascular Outcomes in Trials of Oral Diabetes Medications - A Systematic Review
Elizabeth Selvin et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies
Ajay D. Rao et al.
DIABETES CARE (2008)
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes -: The PERISCOPE randomized controlled trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Secular decline in mortality from coronary heart disease in adults with diabetes mellitus: cohort study
Ane Cecilie Dale et al.
BRITISH MEDICAL JOURNAL (2008)
Cardiovascular safety of rosiglitazone
Ronald L. Krall
LANCET (2007)
Rinnonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes: reply
Lars Ryden et al.
EUROPEAN HEART JOURNAL (2007)
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes
Markolf Hanefeld et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes - A randomized trial
Theodore Mazzone et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin
JMM Evans et al.
DIABETOLOGIA (2006)
Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies
R Huxley et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
E Selvin et al.
ANNALS OF INTERNAL MEDICINE (2004)
Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes
JA Johnson et al.
DIABETES CARE (2002)
Mortality and causes of death in the WHO multinational study of vascular disease in diabetes
NJ Morrish et al.
DIABETOLOGIA (2001)
Myocardial infarction in diabetic vs non-diabetic subjects - Survival and infarct size following therapy with sulfonylureas (glibenclamide)
A Klamann et al.
EUROPEAN HEART JOURNAL (2000)
分享论文
